The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
New Data Demonstrates Link Between Gout and Cardiovascular Disease
December 20th 2019Monosodium urate (MSU) deposits detected by dual-energy computed tomography (DECT) are common in patients with gout and are associated with higher coronary calcium scores, researchers recently reported in JAMA Cardiology.
Do we need one more test to diagnose gout-related CVD?
December 20th 2019The suggestion that DECT scans might add to our diagnostic ability to detect cardiac disease may be imprudent because we have tests at our disposal and have little need to increase diagnostic costs. Good clinical judgement, paying attention to traditional risk factors and to red flags, will increase the number of asymptomatic cardiac patients we choose to study with conventional methods.
Diabetes and RA: Explaining the Similarities
December 19th 2019Rheumatoid arthritis and type 2 diabetes mellitus share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes. In this slideshow, we highlight some of the similarities.
Top 12 Rheumatology Books of 2019
December 18th 2019In this slideshow, we review the year's most noteworthy new books in rheumatology as selected by BookAuthority.com. This is by no means a comprehensive list, but it offers a good look at the diverse selections of rheumatology books published this year.
10 Notable Advances in Rheumatology from 2019
December 18th 2019There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements.
Our Picks for 2019's Top RA Studies
December 18th 2019Studies that explore the efficacy and safety of JAK inhibitors for rheumatoid arthritis are among those we selected as most noteworthy in 2019. Also, at the top of the list, a study that shows glucocorticoids, not necessarily biologics, raise the infection risk after joint replacement surgery. Learn more in this slideshow.
2019's Top Treatment Advances in Lupus
December 18th 20192019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
Report Shows Drug Costs Take Precedence Over Patients' Well-Being
December 13th 2019Xcenda, an AmerisourceBergen company, has just published a white paper that demonstrates the prevalence of step therapy and its potential negative impact on rheumatology patients. The authors of the report say the practice doesn’t always have the best interest of patents in mind and payers don't entirely disagree. Learn more in this report.
Sprifermin Improves Cartilage Thickness, but Clinical Benefit Uncertain
December 12th 2019Intra-articular administration of sprifermin statistically increases total femorotibial joint cartilage thickness in individuals with symptomatic radiographic knee osteoarthritis, but the clinical importance and duration of the effect are uncertain, say researchers writing recently in JAMA.
Nurse Practitioner Q&A: Screen Risk Factors for Blood Clot Disorder
December 12th 2019Blood clots can cause critical or lethal problems in patients, and individuals with antiphospholipid syndrome can experience these events at any location in their bodies. However, there’s not a great deal of clarity on which risk factors are most significant for this condition. In this Q&A, we feature a conversation with Eileen J. Lydon, ANP-BC, a rheumatology nurse practitioner at New York University Langone Orthopedic Hospital, who recently spoke on recommendations for treating patients with antiphospholipid syndrome.
Interleukin Inhibitors May Raise Infection, Cancer Risks
December 12th 2019Among the most noteworthy in 2019: Treatment of rheumatologic diseases with interleukin inhibitors may raise patients’ risks for serious and opportunistic infections and possibly also cancer, researchers reported in JAMA Network Open in October.
Commentary: Infections and Cancer More Common in Rheumatology Than Previously Thought
December 12th 2019Among the year's most noteworthy findings in rheumatology, includes a systemic review and meta-analysis that provides a better understanding of how common infections and cancer really are in patients treated with interleukin (IL) inhibitors. In this article, Dr. Murray offers his personal perspectives on the findings.
Number Needed to Harm: Opportunistic Infections of IL Inhibitors in Rheumatology
December 11th 2019Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
Physiotherapy Improves Outcomes in Ankylosing Spondylitis
December 5th 2019Physiotherapy is beneficial in patients with ankylosing spondylitis and while more research is needed, expanding traditional exercise programs to include aerobic and cardiorespiratory components along with patient education may improve outcomes for patients with non-radiographic axial spondyloarthritis as well.
Ankylosing Spondylitis Cycle Through Treatment Options
December 5th 2019Swedish researchers writing in Arthritis Research & Therapy earlier this year report that more than half (54%) of patients discontinue their first TNFi treatment within five years and those who remain on a TNF inhibitor treatment receive a lower dose.
Who prescribes more treatments for PsA? Rheumatologists or dermatologists?
December 3rd 2019In this month's psoriatic arthritis quiz, we revisit studies presented at the American College of Rheumatology annual meeting last month. Included here is one that highlights interesting trends in prescribing practices by physicians from different specialties. Which specialty is more likely to prescribe more medications?
4 Factors Associated With Ankylosing Spondylitis Progression
November 27th 2019Nearly one-quarter of patients with ankylosing spondylitis experienced disease progression over time, with male sex, presence of baseline damage, active disease state, and higher inflammatory markers predictive of spinal progression, while treatment with tumor necrosis factor (TNF) inhibitors slowed the progression rate, say researchers recently writing in Arthritis Care & Research.
Sustained Remission in RA Fails with Programmed Infliximab Treatment
November 27th 2019A new discontinuation strategy for infliximab in patients with rheumatoid arthritis, in which the biologic dose was determined by the serum level of tumor necrosis factor (TNF)-α, was unsuccessful for sustained biologic-free remission, say researchers recently writing in Annals of the Rheumatic Diseases.
Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases
November 27th 2019Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.
JIA Disease Activity Persists, Despite Lower Uveitis, Major Joint Surgery Rates
November 27th 2019While the need for orthopedic surgery and the presence of uveitis have diminished over the past 20 years in children with juvenile idiopathic arthritis (JIA), disease activity is present more than 50 percent of the time, say researchers recently writing in Arthritis Research and Therapy.
Ultra-Low Rituximab Dose in RA Fails to Meet Non-Inferiority
November 27th 2019Ultra-low doses of rituximab (Rituxan, MabThera) used as maintenance treatment for rheumatoid arthritis in patients who responded well to this agent did not show non-inferiority, but could nevertheless be considered in clinical practice, say researchers recently writing in The Lancet Rheumatology.